Adalimumab

Rheumatology

Rheumatology · Anti-TNFα monoclonal antibody

Adalimumab

Dose

40 mg SC every 2 weeks (loading regimens differ in IBD).

Contraindications

  • Active infection or untreated latent TB
  • NYHA III–IV heart failure
  • Demyelinating disease

Use

RA, psoriatic arthritis, ankylosing spondylitis, Crohn's, ulcerative colitis, uveitis.

Monitoring

Screen for latent TB, hepatitis B/C, HIV before starting; watch for infection and demyelination.

Side effects

  • Injection-site reactions
  • Serious/opportunistic infection
  • TB reactivation
  • Drug-induced lupus

Always confirm dose against your local formulary / BNF before prescribing.

WardRound

WardRound

Clinical Decisions in Seconds